Clinical trial
A Phase 2b, Multi-center, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects With Type 2 Diabetes Mellitus
NCT02390050 is registered in ClinicalTrials.gov with Theracos as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Multi-center, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects With Type 2 Diabetes Mellitus
- Lead sponsor
- Theracos
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 12, 2015
- Completion date
- June 3, 2016
- Enrollment
- 292 (actual)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.